Ngomhlaka-31 kuNtulikazi, i-AstraZeneca kanye ne-Merck & Co. bamemezele ngokuhlanganyela ukuthi umuthi wabo we-PARP inhibitor uLynparza, kanye ne-Abiraterone kanye ne-prednisolone, usuvunyelwe eShayina ekwelapheni iziguli ezindala ezinomdlavuza we-prostate omelana nomdlavuza we-prostate (mCRPC) othwala i-germline noma i-somatic BRCA mutations (gBRCAm noma sBRCAm).
Njengamanje, kusenezivivinyo eziningi zemitholampilo zobuchwepheshe obusha bokulwa nomdlavuza eShayina ezifuna iziguli. Ukubonisana ngemithi emisha kanye nobuchwepheshe, ungaxhumana noMnyango Wezizwe Ngezizwe Wesibhedlela iBeijing South Region Oncology.
Inombolo yocingo: 4008803716
I-ID ye-WeChat: 17801183037
I-imeyili：myimmnet@163.com
I-Lynparza (olaparib) iyi-inhibitor ye-PARP yokuqala ekilasini kanye nokwelashwa kokuqala okuqondiswe kukho ukuvimba impendulo yomonakalo we-DNA (DDR) kumaseli/amathumba anokuntuleka kwe-HRR, njengokuguqulwa kwezakhi zofuzo ku-BRCA1 kanye/noma i-BRCA2. Ukuvinjelwa kwe-PARP nge-Lynparza kuholela ekubambeni i-PARP eboshelwe ekuqhekekeni kwe-DNA eyodwa, ukumiswa kwamafoloko okuphindaphinda, ukuwa kwawo kanye nokukhiqizwa kokuqhekeka kwe-DNA kabili kanye nokufa kwamaseli omdlavuza.
Lokhu kuvunywa kwakusekelwe kakhulu emiphumeleni yokuhlaziywa kweqembu elincane evela kumaqembu omhlaba wonke kanye namaShayina okuhlolwa kwe-PROpel Phase III. I-PROpel iyisilingo somtholampilo seSigaba III esingahleliwe, esingaboni kabili, esiphakathi nendawo esihlola ukusebenza kahle, ukuphepha, kanye nokubekezeleleka kwe-Lynparza ngokuhlanganiswa ne-Abiraterone kanye ne-prednisolone uma kuqhathaniswa ne-placebo kanye ne-Abiraterone kanye ne-prednisolone ezigulini zesilisa ezine-mCRPC ezingakaze zithole i-chemotherapy noma ukwelashwa okusha kwe-hormonal (NHA) esigabeni se-mCRPC.
Idatha evela eqenjini lomhlaba wonke leziguli ezinezinguquko ze-BRCA ibonise ukuthi i-Lynparza kanye ne-Abiraterone ibonise ukuthuthuka okubalulekile emtholampilo ekusindeni okungenazo izinguquko ze-x-ray (rPFS) uma kuqhathaniswa ne-Abiraterone monotherapy. Ukuhlaziywa kweqembu elincane leziguli ezinezinguquko ze-BRCA eqenjini lomhlaba wonke kwembule ukuthi i-Lynparza ehlanganiswe ne-Abiraterone inciphise ingozi yokuqhubeka kwesifo noma ukufa ngo-76% kanye nengozi yokufa ngo-70%. I-rPFS ephakathi nendawo kanye nokusinda okuphelele okuphakathi nendawo (OS) eqenjini le-Lynparza kanye ne-Abiraterone bekungakafinyelelwa, kanti i-rPFS ephakathi nendawo kanye ne-OS ephakathi eqenjini le-Abiraterone monotherapy bekuyizinyanga ezingu-8 nezinyanga ezingu-23, ngokulandelana.
Njengamanje, kusenezivivinyo eziningi zemitholampilo zobuchwepheshe obusha bokulwa nomdlavuza eShayina ezifuna iziguli. Ukubonisana ngemithi emisha kanye nobuchwepheshe, ungaxhumana noMnyango Wezizwe Ngezizwe Wesibhedlela iBeijing South Region Oncology.
Inombolo yocingo: 4008803716
I-ID ye-WeChat: 17801183037
Email：myimmnet@163.com
Isikhathi sokuthunyelwe: Agasti-07-2025